Reviva Q2 business update

 Second Quarter 2022 and Recent Business Highlights

• Enrollment update reporting over 20% of the approximately 400 patients planned for pivotal Phase 3 trial already enrolled (July 2022)
• Developing Phase 2a trial protocols for studies of brilaroxazine in attention deficit hyperactivity disorder (ADHD) and pulmonary arterial hypertension (PAH) (July 2022)
• Hosted key opinion leader webinar on brilaroxazine for schizophrenia and other neuropsychiatric disorders, featuring presentations by Leslie Citrome, MD (New York Medical College) & Larry Ereshefsky, PharmD (Apex Innovative Sciences) (May 2022)
  

Anticipated Milestones and Events

• Enrollment initiation at sites in Europe and India for RECOVER Phase 3 study expected in Q3 2022
• Topline data for pivotal Phase 3 trial evaluating brilaroxazine for the treatment of schizophrenia anticipated in mid-2023
• May initiate Phase 2a studies in bipolar disorder, major depressive disorder (MDD), attention deficit hyperactive disorder (ADHD), pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF) subject to the receipt of non-dilutive financing
• Pursue strategic partnership opportunities for the development of our pipeline
• Evaluate grant and other non-dilutive financing opportunities for product candidates from Federal and State Healthcare Agencies and Foundations

https://www.globenewswire.com/news-release/2022/08/15/2498581/0/en/Reviva-Pharmaceuticals-Holdings-Inc-Reports-Second-Quarter-2022-Financial-Results-and-Recent-Business-Highlights.html